Oligometastatic Prostate Cancer
Conditions
Brief summary
Currently, despite the advent of next-generation imaging has improved the detection of Oligometastatic prostate cancer (OMPC), prognostic biomarkers able to stratify patients and monitor treatment response are lacking and urgently needed. Mounting evidence suggests that molecular profiling of the disease and host immune activity evaluation can reveal OMPC heterogeneity and address the above unmet clinical need. This study aims at combining the analysis of several biomarkers to improve the prognostic stratification of OMPC patients
Detailed description
Currently, despite the advent of next-generation imaging has improved the detection of Oligometastatic prostate cancer (OMPC), prognostic biomarkers able to stratify patients and monitor treatment response are lacking and urgently needed. Mounting evidence suggests that molecular profiling of the disease and host immune activity evaluation can reveal OMPC heterogeneity and address the above unmet clinical need. Liquid biopsy, defined as the sampling and analysis of tumor-derived analytes \[i.e.: circulating tumor cells (CTCs), or circulating tumor DNA (ctDNA)\] from blood, represents a powerful tool to assess in real-time the evolving landscape of cancer, identify prognostic and predictive biomarkers and detect resistance to therapies in several cancers, including Prostate Cancer (PC). Additionally, the same blood sample allows the profiling of tumor-associated components, such as circulating immune cells, which may give clues at the systemic level about the dynamic and complex host-tumor interaction. It is non-invasive, easily repeatable, and cost-effective. In this regard, preliminary results derived from clinical studies indicate that the analysis of tumor material circulating in peripheral blood, combined with the study of the host immune response might be pivotal. This study aims at combining the analysis of several biomarkers, associated with both tumor (CTC and cfDNA) and host (TCR), with a micro-invasive approach, such as liquid biopsy, to improve the prognostic stratification of OMPC patients compared to conventional laboratory test (PSA) and imaging exams (Choline- or PSMA-PET imaging).
Interventions
None listed
Sponsors
Centro di Riferimento Oncologico - Aviano
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Inclusion criteria
Retrospective cohort * \>18 years old; * Patients previously included in the ADAPT-CTC trial * Signing written informed consentInclusion Criteria: Prospective cohort * \>18 years old * Histologic confirmation (primary or metastatic tumor) of Acinar Adenocarcinoma of Prostate * Hormone-sensitive OMPC defined as ≤3 metachronous metastases (bone and/or lymph node) detected within the past 6 months with Choline/PSMA PET-CT following prostate specific antigen (PSA) rising after primary treatment (surgery and/or radiotherapy) with curative intent as defined by European Association of Urology criteria (EAU). * Controlled primary tumor * Prior salvage treatment to the primary prostate cancer is allowed. * PSA ≤ 50 ng/mL * Testosterone ≥ 0.5 ng/mL * ADT associated to the primary treatment concluded more than 6 months prior to the enrollment. * Patients eligible for a course of SBRT on bone and/or lymph node metastatic sites * Patients must have a life expectancy ≥ 12 months and an ECOG performance status ≤ 2 * Patients must have normal organ and marrow function defined as: * Leukocytes ≥2000/µL * Absolute Neutrophil Count ≥1000/µL * Platelets ≥50000/µL * Patients amenable to understand and sign written informed consent documents
Exclusion criteria
Prospective cohort * Spinal cord compression or impending spinal cord compression. * Suspected pulmonary and/or liver metastases * Patient receiving any other investigational agents * Patient is participating in a concurrent treatment protocol * Prior treatments for hormone-sensitive OMPC * Serum creatinine \> 3 times the upper limit of normal. * Total bilirubin \> 3 times the upper limit of normal. * Liver Transaminases \> 5-times the upper limit of normal. * Unable to lie flat during or tolerate PET/CT or SBRT. * Previous history of cancer other than non-melanoma skin cancer in the last 5 years * Traumatic bone events in the 4 weeks before PET
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validation of the prognostic significance of CTCs in a prospective cohort of OMPC patients undergoing SBRT | up to 3 years | To verify if a cut-off value of ≥5 CTC/7.5 mL of blood is prognostic of worst outcome in terms of distant progression-free survival (DPFS). Prognostic value will be measured as hazard ratio and relative 95% confidence intervals. DPFS will be defined as the time between the first day of SBRT and the detection at restaging imaging of clinical disease outside the treatment field |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biochemical-PSF and TCR | up to 3 years | Evaluate the relation between TCR values and biochemical PFS defined as the time between the first day of SBRT to the PSA increase ≥ 25% and ≥ 2 ng/mL if PSA was ≥ 2 ng/mL from baseline, or a PSA increase ≥ 25% if PSA was \< 2 ng/mL. |
| Identify signatures in cfDNA of prognostic significance in terms of Biochemical-PSF | up to 3 years | Association between the presence of a combination of specific tumour mutations detected in cfDNA and Biochemical-PSF defined as the time between the first day of SBRT to the PSA increase ≥ 25% and ≥ 2 ng/mL if PSA was ≥ 2 ng/mL from baseline, or a PSA increase ≥ 25% if PSA was \< 2 ng/mL. |
| Distant-PSF and CTC | up to 3 years | Evaluate the relation between CTC number and its variation and distant PFS defined as the time between the first day of SBRT to the detection at restaging imaging of clinical disease outside the treatment field obtained after biochemical progression |
| Distant-PSF and TCR | up to 3 years | Evaluate the relation between TCR values and distant PFS defined as the time between the first day of SBRT to the detection at restaging imaging of clinical disease outside the treatment field obtained after biochemical progression |
| Identify signatures in cfDNA of prognostic significance in terms of Distant-PSF | up to 3 years | association between the presence of a combination of specific tumour mutations detected in cfDNA and distant PFS defined as the time between the first day of SBRT to the detection at restaging imaging of clinical disease outside the treatment field obtained after biochemical progression |
| Local control and CTC | up to 3 years | Evaluate the relation between CTC number and its variation and local control defined as no evidence of disease in the treatment field at restaging imaging obtained after biochemical progression |
| Local control and TCR | up to 3 years | Evaluate the relation between TCR values and local control defined as no evidence of disease in the treatment field at restaging imaging obtained after biochemical progression |
| Identify signatures in cfDNA of prognostic significance in terms of Local control | up to 3 years | association between the presence of a combination of specific tumour mutations detected in cfDNA and local control defined as no evidence of disease in the treatment field at restaging imaging obtained after biochemical progression |
| ADT-free survival and CTC | up to 3 years | Evaluate the relation between CTC number and its variation and ADT-FS defined as time between the first day of SBRT to the start of palliative ADT |
| ADT-free survival and TCR | up to 3 years | Evaluate the relation between TCR values and ADT-FS defined as time between the first day of SBRT to the start of palliative ADT |
| Biochemical-PSF and CTC | up to 3 years | Evaluate the relation between CTC number and its variation and biochemical PFS defined as the time between the first day of SBRT to the PSA increase ≥ 25% and ≥ 2 ng/mL if PSA was ≥ 2 ng/mL from baseline, or a PSA increase ≥ 25% if PSA was \< 2 ng/mL. |
| time to castration resistant Prostate Cancer and CTC | up to 3 years | Evaluate the relation between CTC number and its variation and TTCR defined as the time between the first day of SBRT to the PSA ≥ 2 ng/mL and Testosterone levels \< 0.5 ng/mL |
| time to castration resistant Prostate Cancer and TCR | up to 3 years | Evaluate the relation between TCR values and TTCR defined as the time between the first day of SBRT to the PSA ≥ 2 ng/mL and Testosterone levels \< 0.5 ng/mL |
| Identify signatures in cfDNA of prognostic significance in terms of time to castration resistant Prostate Cancer | up to 3 years | association between the presence of a combination of specific tumour mutations detected in cfDNA and TTCR defined as the time between the first day of SBRT to the PSA ≥ 2 ng/mL and Testosterone levels \< 0.5 ng/mL |
| Overall survival and CTC | up to 3 years | Evaluate the relation between CTC number and its variation and OS defined as the time between the first day of SBRT to the time of death. |
| Overall survival and TCR | up to 3 years | Evaluate the relation between TCR values and OS defined as the time between the first day of SBRT to the time of death. |
| Identify signatures in cfDNA of prognostic significance in terms of Overall survival | up to 3 years | association between the presence of a combination of specific tumour mutations detected in cfDNA and OS defined as the time between the first day of SBRT to the time of death. |
| TCR values | up to 3 years | Median of TCR diversity, clonality and fold change before and after SBRT |
| cfDNA | up to 3 years | Frequency of selected tumour mutations in cfDNA |
| prognostic value of the combination of different biomarkers | up to 3 years | difference in distant-PFS probability between subgroups of patients carrying different combination of circulating biomarkers. Distant PFS will be defined as the time between the first day of SBRT to the detection at restaging imaging of clinical disease outside the treatment field obtained after biochemical progression |
| Identify signatures in cfDNA of prognostic significance in terms of ADT-free survival | up to 3 years | association between the presence of a combination of specific tumour mutations detected in cfDNA and ADT-FS defined as time between the first day of SBRT to the start of palliative ADT |
Countries
Italy
Contacts
Primary ContactFabio Matrone, MD
Outcome results
None listed